204 related articles for article (PubMed ID: 9932078)
21. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
22. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
23. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
24. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.
Gao H; Zhang X; Chen Y; Shen H; Pang T; Sun J; Xu C; Ding J; Li C; Lu W
Bioorg Med Chem Lett; 2005 Jul; 15(13):3233-6. PubMed ID: 15913996
[TBL] [Abstract][Full Text] [Related]
26. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
Pindur U; Lemster T
Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
[TBL] [Abstract][Full Text] [Related]
27. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.
Morrell A; Antony S; Kohlhagen G; Pommier Y; Cushman M
Bioorg Med Chem Lett; 2004 Jul; 14(14):3659-63. PubMed ID: 15203138
[TBL] [Abstract][Full Text] [Related]
29. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
30. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
31. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerase I poisons.
Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
[No Abstract] [Full Text] [Related]
33. Topoisomerases of kinetoplastid parasites: why so fascinating?
Das BB; Sengupta T; Ganguly A; Majumder HK
Mol Microbiol; 2006 Nov; 62(4):917-27. PubMed ID: 17042788
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerases and topoisomerase inhibitors.
Giaccone G
Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
[TBL] [Abstract][Full Text] [Related]
35. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
36. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
37. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
Pommier Y; Pourquier P; Fan Y; Strumberg D
Biochim Biophys Acta; 1998 Oct; 1400(1-3):83-105. PubMed ID: 9748515
[TBL] [Abstract][Full Text] [Related]
39. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
Pommier Y
Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
[TBL] [Abstract][Full Text] [Related]
40. Clinical trials using irinotecan.
Houghton PJ; Santana VM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]